Trial Profile
KReal Study - Real World Experience of a Nucleoside-sparing Regime - Raltegravir +Lopinavir/Ritonavir
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Mar 2016
Price :
$35
*
At a glance
- Drugs Lopinavir/ritonavir (Primary) ; Raltegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms KReal
- 01 Mar 2016 New trial record